- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.06. | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million | 2 | Cision News | ||
| 22.06. | Curasight A/S announces its intention to carry out a directed issue of shares | 1 | Cision News | ||
| 08.06. | Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT in Aggressive Brain Cancer (Glioblastoma) | 395 | PR Newswire | COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial... ► Artikel lesen | |
| 28.05. | CURASIGHT: Interim report Q1 2026 | 2 | Cision News | ||
| 26.04. | CURASIGHT: Major Shareholding Notification - share transfer and ownership restructuring - related party transaction | 2 | Cision News | ||
| 25.03. | Resolutions of the Annual General Meeting 2026 of Curasight A/S | 2 | Cision News | ||
| 10.03. | CURASIGHT: Notice of Annual General Meeting 2026 | 1 | Cision News | ||
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 06.03. | Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade | 1 | Cision News | ||
| 17.02. | Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston | 311 | PR Newswire | COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ -- Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies... ► Artikel lesen | |
| 09.02. | CURASIGHT: Major Shareholding Notification | 4 | Cision News | ||
| 12.01. | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas | 513 | PR Newswire | Clear uptake of uTREAT in aggressive brain cancer (glioblastoma)Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and... ► Artikel lesen | |
| 05.01. | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week | 388 | PR Newswire | COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" - (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain... ► Artikel lesen | |
| 18.12.25 | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT in Brain Cancer | 1.000 | PR Newswire | Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT belonging to Curasight's treatment platformNo patient safety issues were reported The dosing... ► Artikel lesen | |
| 08.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 08.12.2025 | 953 | Xetra Newsboard | The following instruments on XETRA do have their first trading 08.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.12.2025
Aktien
1 KYG4600C1107 Hope Life International... ► Artikel lesen | |
| 26.11.25 | Curasight's uTREAT Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment | 413 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREATSite given green light by European Medicines Agency (EMA) and is now open for patient... ► Artikel lesen | |
| 26.08.25 | Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT in brain cancer patients | 341 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight's treatment platform.Initiation of the study marks a key... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,335 | -0,66 % | AKTIEN IM FOKUS 2: Danaher enttäuscht Anleger - Auch Sartorius-Kurs leidet | (neu: Kurse mit Danaher im offiziellen Handel, Analystenstimmen) FRANKFURT/NEW YORK (dpa-AFX) - Der Quartalsbericht von Danaher hat im Diagnostikbereich am Dienstag international eine Welle der Enttäuschung... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,680 | +0,15 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| TARSUS PHARMACEUTICALS | 58,66 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| PRAXIS PRECISION MEDICINES | 324,95 | -0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,430 | -0,04 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,26 | -0,01 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| DISC MEDICINE | 74,12 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 52,95 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,740 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 19,110 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,690 | 0,00 % | Vir Biotechnology: Abgang des Finanzchefs schickt Aktie auf Talfahrt | ||
| TANGO THERAPEUTICS | 26,630 | 0,00 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| EDGEWISE THERAPEUTICS | 40,790 | -0,12 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 45,700 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis | WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 21,860 | +0,97 % | Scribe Therapeutics Inc.: Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering | ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR... ► Artikel lesen |
Das Unternehmen CURASIGHT A/S kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,310 Euro und damit -7,23 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.